FMP
Adial Pharmaceuticals, Inc.
ADIL
NASDAQ
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
2.17 USD
-0.15 (-6.91%)
About
ceo
Mr. Cary John Claiborne MBA
sector
Healthcare
industry
Biotechnology
website
https://www.adialpharma.com
exchange
NASDAQ
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
CIK
0001513525
ISIN
US00688A2050
CUSIP
00688A106
Address
1180 Seminole Trail
Phone
434 422 9800
Country
US
Employee
4
IPO Date
Jul 27, 2018
Summary
CIK
0001513525
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00688A106
ISIN
US00688A2050
Country
US
Price
2.17
Beta
1.53
Volume Avg.
6.46M
Market Cap
8.8M
Shares
-
52-Week
0.77-14.0
DCF
1.98
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.44
P/B
-
Website
https://www.adialpharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ADIL News
It looks like there's no news available.
